{"id":"deb-tace-plus-pd-1-inhibitor","safety":{"commonSideEffects":[{"rate":null,"effect":"Post-embolization syndrome (fever, pain, nausea)"},{"rate":null,"effect":"Immune-related adverse events (fatigue, rash, hepatotoxicity)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DEB-TACE (drug-eluting bead transarterial chemoembolization) is a locoregional therapy that combines chemotherapy-loaded beads with vascular embolization to target hepatocellular carcinoma. The addition of a PD-1 inhibitor blocks the PD-1/PD-L1 checkpoint, enhancing T-cell activation and anti-tumor immunity. This combination aims to synergize local tumor destruction with systemic immune activation.","oneSentence":"DEB-TACE delivers chemotherapy directly to liver tumors via embolic beads while a PD-1 inhibitor simultaneously unleashes anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:52.137Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC), unresectable or advanced stage"}]},"trialDetails":[{"nctId":"NCT04229355","phase":"PHASE3","title":"DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2021-02-02","conditions":"Hepatocellular Carcinoma","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DEB-TACE plus PD-1 inhibitor","genericName":"DEB-TACE plus PD-1 inhibitor","companyName":"Guangxi Medical University","companyId":"guangxi-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DEB-TACE delivers chemotherapy directly to liver tumors via embolic beads while a PD-1 inhibitor simultaneously unleashes anti-tumor immune responses. Used for Hepatocellular carcinoma (HCC), unresectable or advanced stage.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}